Immunity | Mast cells regulate lung inflammation through PGE2-sST2
Severe asthma and sinus disease are consequences of type 2 inflammation (T2I), mediated by interleukin (IL)-33 signaling through its membrane-bound receptor, ST2. Inhibiting IL-33 induced lung inflammation may be an effective way to control asthma. Soluble (s)ST2 reduces available IL-33 and limits T2I, but little is known about its regulation.
Recently, A team led by Joshua A. Boyce from Harvard Medical School published an article in the journal Immunity, titled Mast cells control lung type 2 inflammation via prostaglandin E2-driven soluble ST2. It is found that prostaglandin PGE2 can regulate respiratory mucosal mast cells, promote the production of sST2 from mast cells, and inhibit lung inflammation, which provides an important basis for the future treatment of lung inflammation and asthma.
Beijing Sungen Biomedical Technology Co., Ltd. with the mission of "Innovate to lead the future and benefit human health", is committed to developing FIC (First in class) antibody drugs, focusing on unmet clinical needs, and striving to become the world's leading antibody research and development (R & D) enterprise.
As one of bispecific antibody companies, we will do our best to meet all the needs of customers.
You must be logged in to post a comment.